TIGIT and neoplasm: Dual blockade of CD96 with PD-1, PD-L1, TIGIT, or CTLA-4 increases antitumor response, and triple blockade of CD96, PD-1 and TIGIT yields the highest level of antitumoral immunity in various mouse tumor models [108].